Short-term results of percutaneous closure of a patent foramen ovale guided by transoesophageal echocardiography in patients with cryptogenic stroke: a retrospective study

Yilong Guo1,2†, Zhensu Shi2†, Yin Zheng3, Caichan Xie2, Jiao Yi2, Zelun Chen2, Yue Shu2,3*† and Dexing Zhou2*†

Abstract

Background: A patent foramen ovale (PFO) is a risk factor for cryptogenic stroke (CS), and interventional therapy for PFO can reduce the recurrence rate of CS. However, interventional therapies are primarily guided by X-ray imaging, and data on regular post-surgical follow-up with the transthoracic ultrasound foaming test (UFT) are rare. Thus, this study aimed to assess the short-term (12 months) results of PFO occlusion guided by transoesophageal echocardiography (TEE) and the results of regular UFTs.

Methods: Clinical records, echocardiographic data, and UFT results of 75 patients who underwent interventional therapy for PFO and CS were retrospectively analysed. The patients were grouped according to their preoperative UFT results: group A (n = 21), small volume of right-to-left shunts; group B (n = 22), moderate volume of right-to-left shunts; and group C (n = 32), large volume of right-to-left shunts. All patients were treated with an Amplatzer occluder under TEE guidance. UFT follow-up was conducted regularly until 12 months after surgery.

Results: No significant differences in preoperative data, length of hospital stay, or operative time were noted between the groups (p > 0.05). The length of the PFO and diameter of the occluder differed between the groups as follows: group A = group B < group C (p < 0.001). Notably, 1 patient in group C developed recurrent stroke 11 months postoperatively, and 2 patients in group C developed atrial arrhythmia, which improved after 3 months of antiarrhythmic treatment. However, 19 patients still had positive UFT results 12 months postoperatively. Furthermore, the positive UFT rate 12 months postoperatively differed between the groups as follows: group A = group B < group C.
Background
The incidence of ischaemic stroke in China has been increasing annually; despite extensive examination, the aetiology is still unclear in approximately 40% of patients with stroke, and this is referred to as cryptogenic stroke (CS) [1, 2]. Studies have shown that a patent foramen ovale (PFO) is an independent risk factor for CS, especially in patients < 60 years of age with an atrial septal aneurysm or a large volume of right-to-left shunts [3, 4]. Compared with pharmacological treatments, PFO interventional therapy can significantly reduce the recurrence rate of stroke [5, 6]; therefore, methods of diagnosis and interventional therapies for PFO have been rapidly developed. The transthoracic ultrasound foaming test (UFT) is an important imaging modality that significantly improves the detection rate of PFO [7]; however, most PFO interventional therapies are currently performed using radiography, which is associated with the risks of radiation exposure. Furthermore, follow-up data on postoperative transthoracic UFT are lacking [4, 6]. Hence, this study assessed the short-term (12 months) effects of PFO interventional therapy guided by transoesophageal echocardiography (TEE) and the results of regular transthoracic UFTs after surgery.

Methods
Patients
This retrospective study included data of 78 patients who underwent PFO interventional therapy from April 2019 to July 2020. The inclusion criteria were as follows: (1) a clear diagnosis of CS and PFO; (2) age < 60 years; (3) transthoracic UFT performed strictly according to requirements (before surgery and at 3, 6, 9, and 12 months postoperatively). The exclusion criteria were (1) severe organ dysfunction; (2) atrial fibrillation or atrial flutter diagnosed before surgery; (3) other heart diseases requiring simultaneous surgical treatment; (4) patients with giant left atrium (left atrium diameter > 50 mm). Of these 78 patients, 2 were excluded due to preoperative atrial fibrillation and 1 was excluded due to severe liver disease. Finally, 75 patients were included. This study was approved by the Hainan Medical University Clinic Institutional Review Board. Due to the retrospective design of this study, the need for obtaining patient informed consent was waived.

Transthoracic UFT
First, activated normal saline was prepared using two 10-mL syringes: the first syringe was used to draw 8 mL of normal saline and the other contained 1 mL of air and 1 mL of the patient’s blood. The syringes were connected to a three-way valve, and their contents were rapidly injected back and forth to fully mix the blood, normal saline, and air to obtain 10 mL of activated normal saline [8, 9]. Following this, two syringes were prepared for each patient, each containing 10 mL of activated normal saline.

Second, while the patient was in the supine position, an apical four-chamber view was obtained using transthoracic echocardiography. One syringe of activated normal saline was rapidly injected through the cubital vein of the patient. If a microbubble entered the left atrium within 10 cardiac cycles, it was recognised as a positive result. Subsequently, the patients were asked to perform the Valsalva manoeuvre (thoracic pressure ≥ 40 mmHg) for more than 10 s. The other 10 mL of activated normal saline was rapidly injected through the cubital vein [10]. The number of microbubbles in the left atrium during three cardiac cycles was recorded, and the partial flow of a PFO was graded as follows: no shunt, no microbubbles in the left atrium; small, 1–10 microbubbles in the left atrium; moderate, 11–25 microbubbles in the left atrium; and large, > 25 microbubbles in the left atrium [8, 9].

Third, the patients were divided into three groups according to their transthoracic UFT results: group A, small-volume shunt group; group B, moderate-volume shunt group; and group C, large-volume shunt group.

Surgical methods
All surgeries were performed under general anaesthesia and guided by TEE. The length of the PFO was measured using TEE in the double vena cava section of the
middle oesophagus, and an occluder was selected based on the measured PFO length. The right femoral vein was punctured, and the interventional track was established: right femoral vein—right atrium—PFO—left atrium. An Amplatzer occluder (Abbott Medical, Nathan Lane North Plymouth, MN, USA) was implanted along this track. Before releasing the occluder, the push–pull test was conducted to test the stability of the occluder, and the relationship between the occluder edge and cardiac structure was verified by TEE. After the occluder was released, the interventional catheter was removed, and pressure was applied over the right femoral vein puncture site to secure haemostasis. Finally, the patient returned to the general ward. Echocardiography was performed immediately and 12 h and 24 h after operation. If pericardial tamponade occurred, it was handled in time. Antibiotics were used to prevent infection from 30 min before operation to 24 h after operation. All the surgeries were performed by a single experienced surgeon.

Follow-up
All patients were regularly treated with aspirin for 6 months (3–5 mg/kg/day). At 3, 6, 9, and 12 months postoperatively, all the patients returned to the hospital for transthoracic echocardiography, transthoracic UFT, chest radiography, and electrocardiography. All echocardiography and UFT results were evaluated by two doctors independently. If the reports of these doctors were inconsistent, the opinion of a third doctor was requested, and the opinion of the majority was the final data included in the analysis.

Data collection and processing
Preoperative data included the sex ratio; age; weight, height; comorbidities; heart function; recurrence of stroke before surgery; sequelae of stroke before surgery; right ventricular (RV), left atrial (LA), main pulmonary artery (PA), pulmonary systolic pressures (PSP); pulmonary vascular resistance (PVR); left ventricular end-diastolic diameter (LVEDD); and left ventricular ejection fraction (LVEF).

Intraoperative data collected included the length of the PFO, operative time, and diameter of the occluder. Follow-up data collected included common postoperative complications (pericardial tamponade, occluder migration, and local vascular injury), length of hospital stay, stroke recurrence, atrial fibrillation, atrial flutter, and UFT results.

Statistical analysis
Continuous data are expressed as means ± standard deviation (SD), while categorical variables are expressed as percentages. Between-group comparisons were performed using the one-way analysis of variance, chi-square test, or Fisher’s exact test, as appropriate.

Kaplan–Meier analysis was used to analyse the relationship between UFT results and follow-up time, and Cox regression analysis was used to analyse the effects of various factors on the postoperative UFT results. All statistical data were processed with SPSS version 19.0 (IBM SPSS, Armonk, NY, USA), and a p-value < 0.05 was considered reflective of the statistical significance.

Results
Preoperative information
Group A included 21 patients, with a mean age of 45.05 ± 8.992 years; group B included 22 patients, with a mean age of 45.09 ± 9.314 years; and group C included 32 patients, with a mean age of 41.25 ± 10.352 years. The youngest patient was a 27-year-old man in group C who developed hemiplegia after CS before surgery. There were no significant differences in the preoperative data between the groups. The clinical and echocardiographic characteristics of the study population are presented in Tables 1 and 2, respectively.

Perioperative data
All patients were successfully treated with PFO interventional therapy, and there was no incidence of perioperative pericardial tamponade, occluder migration, cardiac rupture, or malignant ventricular arrhythmia. There were 2 patients with an atrial septal aneurysm in this study, one in group B and the other was in group C. PFO occlusion was performed successfully for both of them. No significant difference was found in the operative time and length of stay between the groups (p > 0.05). The length of PFO differed between the groups as follows: group A = group B < group C (p < 0.001). Patients in group C had significantly larger occluders than those in the other two groups (p < 0.001). The perioperative data of the study population are presented in Table 3.

Follow-up data
All patients in this study were followed up regularly for 12 months. There was no new incidence of migraine, pericardial tamponade, occluder migration, occluder-related valve dysfunction, death, bleeding, or oesophageal perforation within 12 months postoperatively. Only one 38-year-old female patient in group C developed transient recurrent stroke 11 months postoperatively. She was discharged without any sequelae after 7 days of treatment; she still had a positive UFT result 12 months postoperatively. Arrhythmia was not observed in groups A. One patient in group B who experienced supraventricular tachycardia immediately after the operation. The patient’s sinus rhythm
was recovered by increasing the depth of anaesthesia and properly supplementing the blood volume. Two patients in group C developed atrial arrhythmias (alternating atrial fibrillation and atrial flutter) 3 months postoperatively. They were treated with amiodarone (200 mg/day) and recovered after 3 months. Eight patients developed mild chest tightness or chest pain immediately after the operation. However, all of them recovered within 3 months after the operation.

All patients underwent UFT regularly after surgery. The residual shunt on the atrial septum was excluded using transthoracic echocardiography before UFT (Fig. 1). Twelve months after surgery, no patients in group A had a positive UFT (Fig. 2). Notably, 3 and 16 patients in groups B and C, respectively, had positive UFT results (Fig. 3). The number of patients who had positive UFT results 12 months postoperatively differed between the groups as follows: group A = group B < group C (p < 0.05).

### Table 1  Clinical characteristics of the study population

|                          | Group A (n = 21) | Group B (n = 22) | Group C (n = 32) | p value |
|--------------------------|------------------|------------------|------------------|---------|
| Female sex               | 14 (66.67%)      | 11 (50.00%)      | 12 (37.50%)      | 0.119   |
| Age (mean ± SD, years)   | 45.05 ± 8.992    | 45.09 ± 9.314    | 41.25 ± 10.352   | 0.247   |
| Weight (mean ± SD, kg)   | 60.92 ± 7.855    | 59.59 ± 11.548   | 56.72 ± 8.938    | 0.263   |
| Height (mean ± SD, cm)   | 163.05 ± 7.965   | 160.68 ± 7.656   | 160.05 ± 5.224   | 0.287   |
| Diabetes                 | 2 (9.52%)        | 4 (18.18%)       | 1 (3.13%)        | 0.178   |
| Hypertension             | 7 (33.33%)       | 8 (36.36%)       | 7 (21.88%)       | 0.467   |
| Hyperlipidaemia          | 1 (4.76%)        | 4 (18.18%)       | 1 (3.13%)        | 0.112   |
| Heart function (NYHA) I  | 8                | 4                | 7                | 0.462   |
| Heart function (NYHA) II | 10               | 14               | 21               |         |
| Heart function (NYHA) III| 3                | 4                | 4                |         |
| Recurrence stroke before surgery | 3          | 3              | 4               | 0.982   |
| Stroke sequelae before surgery | 1       | 1              | 3               | 0.719   |

SD standard deviation, NYHA New York Heart Association

### Table 2  Echocardiographic characteristics of the study population

|                          | Group A (n = 21) | Group B (n = 22) | Group C (n = 32) | p value |
|--------------------------|------------------|------------------|------------------|---------|
| RV (mm)                  | 23.24 ± 2.879    | 22.05 ± 4.326    | 21.47 ± 4.333    | 0.290   |
| LA (mm)                  | 31.48 ± 5.437    | 29.45 ± 3.776    | 28.69 ± 5.515    | 0.147   |
| PA (mm)                  | 21.29 ± 3.036    | 20.32 ± 2.255    | 20.47 ± 3.233    | 0.500   |
| LVEDD (mm)               | 43.81 ± 2.839    | 42.82 ± 3.187    | 42.72 ± 2.667    | 0.367   |
| LVEF (%)                 | 63.00 ± 6.116    | 65.50 ± 2.596    | 64.98 ± 5.097    | 0.205   |
| PSP (mmHg)               | 22.62 ± 4.031    | 23.09 ± 3.531    | 24.44 ± 2.590    | 0.121   |
| PVR (dyn s cm⁻⁵)         | 150.10 ± 26.474  | 164.55 ± 20.871  | 158.47 ± 24.397  | 0.149   |

RV right ventricular, LA left atrial, PA main pulmonary artery, LVEDD left ventricular end-diastolic diameter, LVEF left ventricular ejection fraction, PSP pulmonary systolic pressure, PVR pulmonary vascular resistance

### Table 3  Perioperative data of the study population

|                          | Group A (n = 21) | Group B (n = 22) | Group C (n = 32) | p value |
|--------------------------|------------------|------------------|------------------|---------|
| Time (min)               | 44.71 ± 25.714   | 35.64 ± 20.984   | 38.50 ± 25.821   | 0.464   |
| Length of PFO (mm)       | 9.03 ± 6.166²    | 10.55 ± 3.546²   | 14.02 ± 3.047¹b | < 0.001 |
| Occluder (mm)            | 19.67 ± 3.055²   | 19.91 ± 3.191²   | 23.25 ± 3.800¹b | < 0.001 |
| Oesophageal bleeding     | 2                | 3                | 3                | 0.866   |
| Length of stay (days)    | 12.24 ± 6.480    | 13.50 ± 8.478    | 13.00 ± 8.658    | 0.875   |

Statistical comparisons: comparison between groups, a p < 0.01; b p < 0.05
PFO patent foramen ovale
The positive UFT results during follow-up are presented in Table 4.

Kaplan–Meier analysis showed that the positive UFT rate gradually decreased during follow-up (Fig. 4). Cox regression analysis revealed that the positive UFT rate in group C was higher than group A ($p = 0.002$) (Fig. 5). There was no significant difference in the positive UFT rate between groups A and B ($p = 0.135$). Moreover, a preoperative large-volume shunt was negatively associated with a negative UFT rate 12 months postoperatively (OR = 0.255, 95% CI: 0.104–0.625). Age, sex, weight, height, RV, PA, PSP, PVR, LVEDD, LVEF, and LA had no significant effect on postoperative UFT results ($p > 0.05$).

**Discussion**

The foramen ovale is an important structure in the foetal heart that allows oxygenated blood to flow from the right atrium into the left atrium and ventricle, which then supplies blood and oxygen to the whole body [11]. After birth, with a decrease in the PA pressure and an increase in LA pressure, the foramen ovale closes spontaneously in approximately 75% of the population [12]. In others, it does not close, resulting in a PFO [13, 14]. Studies have shown that a PFO is a risk factor for CS; hence, studies on interventional therapy for PFO have been increasing for decades [15].

Initially, PFO interventional therapies were guided by X-ray imaging. However, its development was limited by the use of contrast agents and exposure to X-rays. Therefore, surgeons have recently begun to perform PFO interventional closure under the guidance of TEE [16, 17].
In our study, all patients were successfully treated with interventional therapy under TEE guidance, with no pericardial tamponade, death, or other major complications. The most important complications after PFO interventional therapy are recurrent stroke and atrial fibrillation [18, 19]; however, in this study, only 1 patient developed transient recurrent stroke 11 months postoperatively, and 2 patients developed atrial arrhythmias 3 months postoperatively. Therefore, these results suggest that PFO interventional therapy guided by TEE could lead to satisfactory short-term (12 months) results, which is consistent with the findings of previous studies [17].

Herein, the positive UFT rate gradually decreased. However, there were still 19 patients, most of whom
belonged to group C, with positive UFT results at 12 months postoperatively; this was the most important finding of this study. Previous studies have shown that the recurrence rate of stroke after PFO occlusion in patients with CS is 2.0–5.0% [19], and the reason for this is still unclear. In our study, 1 patient in group C developed transient recurrent stroke 11 months postoperatively, and she still had a positive UFT result at 12 months postoperatively. A positive UFT result after surgery means that microthrombi and microbubbles can still be shunted from the right atrium to the left atrium through the PFO occluder. As the number of patients who developed recurrent stroke postoperatively in this study was small, further statistical analysis could not be conducted. Thus, we cannot rule out the possibility that a persistent positive UFT result after surgery is a risk factor for recurrent stroke. After detailed analysis, there were two possible reasons why 16 patients in group C still had positive UFT results 12 months postoperatively. First, the Amplatzer occluder, which is used worldwide, was used in this study. It has a metal-braided mesh structure without a film on the surface. Therefore, it cannot prevent the passage of microthrombi and microbubbles. However, the occluder is gradually embedded in the intima after it is released. This implies that when the occluder is completely embedded, microthrombi and microbubbles would be unable to pass through it, resulting in a negative UFT result [19, 20]. The present study shows that there are individual differences in the process by which the occluder is embedded. Moreover, patients with a large volume of right-to-left shunts before surgery will have a longer embedding process. Second, in this study, the length of the PFO and the diameter of the occluder in group C were larger than those in group A and group B, whereas the positive UFT rate 12 months postoperatively in group C was higher than that in groups A and B. Furthermore, the diameter of the occluder used in this study was equal to the length of the PFO + 10 mm. Considering all these findings, it could be concluded that with an increase in the PFO length, the diameter of the occluder increases and the embedding process is prolonged; hence, UFT positivity after surgery is observed in the long term.

This study has some limitations, as it was a retrospective, non-randomised study; therefore, some selection bias exists. Further prospective, randomised, large-scale, and long-term studies are required to clarify the changes in UFTs after PFO occlusion and to verify the relationship between postoperative positive UFT results and stroke recurrence.

Conclusions
In patients with PFO and CS, interventional therapy guided by TEE could lead to satisfactory short-term (12 months) outcomes. Although the positive UFT rate gradually decreased, some patients still had positive UFT results at 12 months postoperatively. A large volume of right-to-left shunts and a longer PFO preoperatively were the risk factors for positive UFT results postoperatively. Further studies are required to clarify the relationship between postoperative positive UFT results and stroke recurrence.

Abbreviations
PFO: Patent foramen ovale; CS: Cryptogenic stroke; UFT: Ultrasound foaming test; TEE: Transoesophageal echocardiography; RV: Right ventricular; LA: Left atrial; PA: Main pulmonary artery; PVR: Pulmonary vascular resistance; LVEDD: Left ventricular end-diastolic diameter; LVEF: Left ventricular ejection fraction; SD: Standard deviation.

Acknowledgements
Not applicable.

Author contributions
YG and ZS conceptualised and designed the study. YS and DZ provided administrative support. YZ and JY provided study materials or helped in recruiting patients. ZC and YS collected and assembled all data. CX and DZ analysed and interpreted the data. YG and ZS wrote the manuscript. All authors read and approved the final manuscript.

Funding
This work was supported by a grant from the 2018 medical and health research project of Hainan Province (Grant Number: 1801320114A2008). All transthoracic UFTs after surgery were paid for by this funder.

Availability of data and materials
All data generated or analysed during this study are included in this published article.

Declarations
Ethics approval and consent to participate
This study was approved by the Hainan Medical University Clinic Institutional Review Board, and the need for patient consent was waived due to the retrospective study design. The protocol of this study was performed in accordance with the Declaration of Helsinki.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Medical School of Chinese PLA, Beijing, People’s Republic of China. 2 Department of Cardiovascular Surgery, The Second Affiliated Hospital of Hainan Medical University, 48th of Bai Shui Tang Road, Haikou, Hainan 570311, People’s Republic of China. 3 Department of Special Medical Services, Hainan Cancer Hospital, No. 6th Changbin West 4th Street, Haikou, Hainan 570300, People’s Republic of China.

Received: 14 October 2021   Accepted: 18 April 2022
Published online: 03 May 2022
References

1. Steiner MM, Di Tullio MR, Rundek T, Gan R, Chen X, Liguori C, et al. Patent foramen ovale size and embolic brain imaging findings among patients with ischemic stroke. Stroke. 1998;29:944–8.

2. Hart RG, Miller VT. Cerebral infarction in young adults: a practical approach. Stroke. 1983;14:110–4.

3. Mas JL, Derumeaux G, Guillou B, Massardier E, Hosseini H, Mechtouff L, et al. Patent foramen ovale closure or anticoagulation vs. antplatelets after stroke. N Engl J Med. 2017;377:1011–21.

4. Katsoanos AH, Spence JD, Bogatchi C, Papadopoulou S, Fougoudaki A, et al. Recurrent stroke and patent foramen ovale: a systematic review and meta-analysis. Stroke. 2014;45:3352–9.

5. Kent DM, Dahabreh IJ, Ruthazer R, Furlan AJ, Weimar C, Serena J, et al. Anticoagulant vs. antiplatelet therapy in patients with cryptogenic stroke and patent foramen ovale: an individual participant data meta-analysis. Eur Heart J. 2015;36:2381–9.

6. Elmanihai S, Furlan AJ, Reisman M, Burke D, Vardi M, Wimmer NJ, et al. Predictors of recurrent events in patients with cryptogenic stroke and patent foramen ovale within the CLOSURE I (Evaluation of the STARFlex septal closure system in patients with a stroke and/or transient ischemic attack due to presumed paradoxical embolism through a patent foramen ovale) trial. JACC Cardiovasc Interv. 2014;7:913–20.

7. Katsoanos AH, Psaltopoulou T, Sergentanis TN, Fougoudaki A, Vrettou AR, Ikonomidis I, et al. Transcranial Doppler versus transthoracic echocardiography for the detection of patent foramen ovale in patients with cryptogenic cerebral ischemia: a systematic review and diagnostic test accuracy meta-analysis. Ann Neurol. 2016;79:625–35.

8. Mojadidi MK, Winoker JS, Roberts S, Msaouel P, Zaman M, Gevorgyan R, et al. Accuracy of conventional transthoracic echocardiography for the diagnosis of intracardiac right-to-left shunt: a meta-analysis of prospective studies. Echocardiography. 2014;31:1036–48.

9. Mojadidi MK, Winoker JS, Roberts SC, Msaouel P, Gevorgyan R, Zolty R. Two-dimensional echocardiography using second harmonic imaging for the diagnosis of intracardiac right-to-left shunt: a meta-analysis of prospective studies. Int J Cardiovasc Imaging. 2014;30:911–3.

10. Guo YZ, Gao YS, Guo ZN, Niu PP, Yang Y, Xing YQ. Comparison of different methods of Valsalva maneuver for right-to-left shunt detection by contrast-enhanced transcranial Doppler. Ultrasound Med Biol. 2016;42:1124–9.

11. Dattilo PB, Kim MS, Carroll JD. Patent foramen ovale. Cardiol Clin. 2013;31:401–15.

12. Homma S, Sacco RL. Patent foramen ovale and stroke. Circulation. 2005;112:1063–72.

13. Di Tullio MR. Patent foramen ovale: echocardiographic detection and clinical relevance in stroke. J Am Soc Echocardiogr. 2010;23:144–55.

14. Sun YP, Homma S. Patent foramen ovale and stroke. Circ J. 2016;80:1665–73.

15. Bridges ND, Hellenbrand W, Latson L, Filiano J, Newburger JW, Lock JE. Transcatheter closure of patent foramen ovale after presumed paradoxical embolism. Circulation. 1992;86:1902–8.

16. Akagi T. Transcatheter closure of patent foramen ovale: current evidence and future perspectives. J Cardiol. 2021;77:9–13.

17. Han Y, Zhang X, Zhang F. Patent foramen ovale closure by using transesophageal echocardiography for cryptogenic stroke: single center experience in 132 consecutive patients. J Cardiothorac Surg. 2020;15:11.

18. Teshome MK, Najib K, Nwagbara CC, Akinseye OA, Ibebuogu UN. Patent foramen ovale: a comprehensive review. Curr Probl Cardiol. 2020;45:66.

19. Mojadidi MK, Zaman MO, Eldendy IY, Mahmoud AN, Patel NK, Agarwal N, et al. Cryptogenic stroke and patent foramen ovale. J Am Coll Cardiol. 2018;71:1035–43.

20. Carroll JD, Saver JI, Thaler DE, Smalling RW, Berry S, MacDonald LA. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med. 2013;368:1092–100.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.